Search Result

Results for "

pi4k

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PI4K (18) ATM/ATR (1) Autophagy (1) Enterovirus (1) MAP4K (1) Parasite (11) PI3K (5) PKG (2) Potassium Channel (1) Reference Standards (2) Small Interfering RNA (siRNA) (6) Virus Protease (1)
By Research Areas:	Cancer (3) Infection (15)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (6)

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Oligonucleotides

Targets Recommended: PI4K

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12016

KU-55933 Maximum Cited Publications 62 Publications Verification	ATM/ATR Autophagy	Cancer
KU-55933 is a potent ATM inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-106005

MMV390048 3 Publications Verification	Parasite PI4K	Infection
MMV390048 is a representative of a new chemical class of Plasmodium *PI4K* inhibitor (K_d ^app=0.3 µM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent .

HY-12046

PIK-93 5+ Cited Publications	PI4K PI3K Virus Protease	Cancer
PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC₅₀ of 19 nM, and also inhibits PI3Kγ and PI3Kα with IC₅₀ of 16 nM and 39 nM, respectively.

HY-12912

KDU691	PI4K Parasite	Infection
KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a **Plasmodium PI4K** inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites .

HY-115675

NC03	PI4K	Others
NC03 is a *PI4K2A* inhibitor and reducing agent. NC03 inhibits the activity of *PI4K2A, thereby reducing the production of PI4P* in the cellular compartments where *PI4K2A* functions. NC03 rapidly induces a decrease in *PI4P* pools in the Golgi and endosomal compartments. NC03 reduces *PI4P* production in Rab7-positive late endosomes .

HY-106012

PI4K-IN-1	PI4K PI3K	Cancer
PI4K-IN-1 (compound 44) is a potent *PI4KIII* inhibitor, with pIC₅₀ values of 9.0 and 6.6 for PI4KIIIα and PI4KIIIβ, respectively. PI4K-IN-1 also inhibits PI3Kα/β/γ/δ, with pIC₅₀ values of 4.0/<3.7/5.0/<4.1, respectively .

HY-112435

UCT943	PI4K Parasite	Infection
UCT943 is a next-generation Plasmodium falciparum *PI4K* inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an IC₅₀ of 23 nM .

HY-100603A

(S)-GSK-F1	PI3K PI4K	Infection
(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC₅₀ of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model .

HY-103583

KDU731	PI4K Parasite	Infection
KDU731, an orally active C. parvum *PI4K* inhibitor with an IC₅₀ value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo . KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety .

HY-178775

PI4K-IN-3	PI4K Parasite MAP4K PI3K	Infection
PI4K-IN-3 (Compound 27) is an orally active *PI4K* inhibitor with an IC₅₀ of 1.9  nM for Plasmodium vivax PI4K. PI4K-IN-3 has no hERG channel inhibition and mammalian cytotoxicity. PI4K-IN-3 has significant selectivity against the human MINK1 and *MAP4K4* kinases but with low selectivity against human PI3Kα and PI4Kβ. PI4K-IN-3 has potent antimalarial activity and significantly reduces parasitaemia in NSG mice mouse models of Plasmodium falciparum malaria .

HY-174134

PI4Kβ/PKG-IN-2	PI4K PKG Parasite	Infection
PI4Kβ/PKG-IN-2 (Compound 20) is an orally active dual inhibitor of Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-2 has potent inhibitory effects on Plasmodium. PI4Kβ/PKG-IN-2 is promising for research of malaria .

HY-175557

PI4K-IN-2	PI4K Enterovirus	Infection
PI4K-IN-2 (Compound 30) is a highly selective type III phosphatidylinositol 4-kinase β (PI4KB) inhibitor (IC₅₀=0.015 μM). PI4K-IN-2 is promising for research of human rhinovirus (HRV) .

HY-150598

*CHMFL-PI4K-127*	PI4K PI3K	Infection
CHMFL-PI4K-127 (compound 15g) is an orally active, potent and high selective *PfPI4K* (Plasmodium falciparum PI4K kinase) inhibitor, with an IC₅₀ of 0.9 nM. CHMFL-PI4K-127 exhibits potent activity against 3D7 Plasmodium falciparum, with an EC₅₀ of 25.1 nM. CHMFL-PI4K-127 shows antimalaria efficacy .

HY-175732

PI4Kβ-IN-1	PI4K Parasite	Infection
PI4Kβ-IN-1 is an orally active and selective PI4Kβ inhibitor, with an IC₅₀ of 0.9 nM. PI4Kβ-IN-1 exhibits inhibitory activity against all stages of the P. falciparum life cycle, including blood, liver, and transmission stages. PI4Kβ-IN-1 demonstrates potent antimalarial efficacy in the mouse model infected with Plasmodium falciparum. PI4Kβ-IN-1 can be used for the study of malaria caused by Plasmodium falciparum .

HY-174130

PI4Kβ/PKG-IN-1	Parasite PI4K PKG	Infection
PI4Kβ/PKG-IN-1 (Compound 19) is an orally active dual inhibitor targeting Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-1 exhibits potent antiplasmodial activity. PI4Kβ/PKG-IN-1 is promising for research of malaria .

HY-163765

Antimalarial agent 41	PI4K Potassium Channel	Infection
Antimalarial agent 41 (Compound 17) exhibits antimalarial activity, which inhibits Plasmodium falciparum with an IC₅₀ of 40 nM (NF54 strain) and 76 nM (K1 strain). Antimalarial agent 41 is an inhibitor for P. falciparum phosphatidylinositol-4-kinase β (Pf PI4K) and hERG channel, with an IC₅₀ of 53 nM and 3 μM. Antimalarial agent 41 exhibits cytotoxicity to CHO cells with an IC₅₀ of 34 μM. Antimalarial agent 41 ameliorates the malaria infection and exhibits good pharmacokinetic characters in mouse models .

HY-RS10464

PI4K2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PI4K2A Human Pre-designed siRNA Set A contains three designed siRNAs for PI4K2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PI4K2A Human Pre-designed siRNA Set A PI4K2A Human Pre-designed siRNA Set A

HY-RS20578

Pi4k2a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pi4k2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2a Mouse Pre-designed siRNA Set A Pi4k2a Mouse Pre-designed siRNA Set A

HY-RS10465

PI4K2B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PI4K2B Human Pre-designed siRNA Set A contains three designed siRNAs for PI4K2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PI4K2B Human Pre-designed siRNA Set A PI4K2B Human Pre-designed siRNA Set A

HY-106005R

MMV390048 (Standard)	Reference Standards Parasite PI4K	Infection
MMV390048 (Standard) is the analytical standard of MMV390048 (HY-106005). This product is intended for research and analytical applications. MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 μM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent .

HY-103583R

KDU731 (Standard)	Reference Standards PI4K Parasite	Infection
KDU731 (Standard) is the analytical standard of KDU731 (HY-103583). This product is intended for research and analytical applications. KDU731, an orally active C. parvum PI4K inhibitor with an IC₅₀ value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo . KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety .

HY-RS27086

Pi4k2a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pi4k2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2a Rat Pre-designed siRNA Set A Pi4k2a Rat Pre-designed siRNA Set A

HY-RS26693

Pi4k2b Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pi4k2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2b Rat Pre-designed siRNA Set A Pi4k2b Rat Pre-designed siRNA Set A

HY-RS20189

Pi4k2b Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pi4k2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2b Mouse Pre-designed siRNA Set A Pi4k2b Mouse Pre-designed siRNA Set A

HY-18746

KAI-407	Parasite PI4K	Infection
KAI-407 is an orally active inhibitor of Plasmodium *PI4K* kinase, which can broadly inhibit multiple stages of the parasite lifecycle. KAI-407 exhibits EC₅₀s of for the blood stage of malignant Plasmodium of 81 nM; for the liver schizonts of P. yoelii of 88 nM; and IC₅₀s for the liver schizonts and dormant bodies of P. cynomolgi of 0.64 μM and 0.69 μM respectively. KAI-407 can prevent Plasmodium berghei infection 100%. KAI-407 can be used for the study of vivax malaria .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library	3,814 compounds
Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. Kinase inhibitor library designed by MCE contains 3,814 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Kinase Inhibitor Library

3,814 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3,814 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L009M

Kinase Inhibitor Library Mini	271 compounds
Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available. The MCE Kinase Inhibitor Library Mini contains 271 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

Kinase Inhibitor Library Mini

271 compounds

Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available.

The MCE Kinase Inhibitor Library Mini contains 271 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

Recombinant Proteins Recommended:

PI4K

Species:	Human (3)
Tag:	His (3) GST (3)
Source:	Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703335

	PI4K2A Protein, Human (His, GST) Phosphatidylinositol 4-kinase type 2-alpha; Phosphatidylinositol 4-kinase type II-alpha; pi4k2A; Homo sapiens; Human; Kinase; Transferase; 2.7.1.67	Human	E. coli
	PI4K2A Protein, Human (His, GST) is the recombinant human-derived PI4K2A, expressed by E. coli , with His, GST labeled tag. ,

HY-P701742

	PI4KB Protein, Human (Active, sf9, His, GST) pi4kB; Phosphatidylinositol 4-kinase beta; pi4k-beta; pi4kbeta; PtdIns 4-kinase beta; NpiK; pi4k92; pi4kIII	Human	Sf9 insect cells
	The PI4KB protein is a key enzyme that initiates the production of 1,4,5-trisphosphate inositol (PIP) by phosphorylating phosphatidylinositol (PI). In addition to myo-inositol signaling, it is involved in mitotic Golgi disassembly and Golgi-to-plasma membrane trafficking, which is critical for cell membrane dynamics. PI4KB Protein, Human (sf9, His, GST) is the recombinant human-derived PI4KB protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.

HY-P703333

	PI4K2B Protein, Human (sf9, His, GST) Phosphatidylinositol 4-kinase type 2-beta; Phosphatidylinositol 4-kinase type II-beta; pi4kII-BETA; pi4k2B; Homo sapiens; Human; pi4kII-BETA; Kinase; Transferase; 2.7.1.67	Human	Sf9 insect cells
	PI4K2B Protein, Human (sf9, His, GST) is the recombinant human-derived PI4K2B, expressed by sf9 insect cells , with His, GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

PI4K2A Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PI4K2A Human Pre-designed siRNA Set A contains three designed siRNAs for PI4K2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2a Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Pi4k2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

PI4K2B Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PI4K2B Human Pre-designed siRNA Set A contains three designed siRNAs for PI4K2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2a Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Pi4k2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2b Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Pi4k2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pi4k2b Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Pi4k2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pi4k2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: